GENERAL POLICIES GOVERNING

The Immunotherapy Promise™

A GROUNDBREAKING, COLLABORATIVE CAMPAIGN
BRINGING TOGETHER THE CANCER RESEARCH INSTITUTE
WITH THE ISRAEL CANCER RESEARCH FUND

The Israel Cancer Research Fund (ICRF) is a voluntary charitable organization that receives its total income from private donations. Its main goals are the advancement of cancer research and the training of Israeli scientists in Israel. To that end, funds for cancer research are available to citizens of Israel, both native-born and those who have settled. Funds are not available to visiting scientists. (Proof of Israeli citizenship must be furnished upon request.)

The Cancer Research Institute (CRI) is a nonprofit organization that is dedicated to harnessing the immune system’s power to control and potentially cure all types of cancer. To accomplish this, it funds the most innovative clinical and laboratory research around the world, supports the next generation of the field’s leaders, and serves as the trusted source of information on immunotherapy for cancer patients and their caregivers.

The Immunotherapy Promise, a collaboration between Cancer Research Institute and Israel Cancer Research Fund, will provide funding for qualified scientists at leading universities and research centers throughout Israel with the goal of advancing our understanding of cancer immunotherapy and developing life-extending and saving therapies, novel diagnostic approaches, and/or prevention strategies.

Information on applying for these research grants may be obtained from the ICRF website. For any questions or problems, please send an E-mail message to: ellen.rubin@icrfny.org.

BEFORE ANY APPLICATION WILL BE PROCESSED OR REVIEWED, ALL OF THE REQUIRED ITEMS MUST BE COMPLETED EXACTLY AS REQUESTED; OTHERWISE THE APPLICATION WILL BE RETURNED AUTOMATICALLY AND NOT REVIEWED.

**Timetable for the Awarding of Grants**

<table>
<thead>
<tr>
<th>RECEIVED BY THE ICRF IN NEW YORK</th>
<th>NOTIFICATION OF DECISION</th>
<th>ACTIVATION OF AWARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 7, 2019</td>
<td>July 1, 2019</td>
<td>September 1, 2019</td>
</tr>
</tbody>
</table>
Purpose
This new funding opportunity is aimed at fostering outstanding basic, pre-clinical, and/or translational research in cancer immunology and immunotherapy throughout Israel, with the goal of advancing our understanding of cancer immunotherapy and developing life-extending and saving therapies, novel diagnostic approaches, and/or prevention strategies.

Eligibility
Candidates for The Immunotherapy Promise grants must be Israeli citizens and hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. Research supported by the award must be conducted at medical schools and research centers in Israel. Please note that the CRI/ICRF Immunotherapy Promise Grants do not support research at for-profit institutions.

Duration and Amount of the Award
Together, CRI and ICRF will provide a maximum of four grants at a level of $75,000 per year over two years ($150,000 total) to qualified scientists at leading universities and research centers in Israel. The funds may be used for salary, technical assistance, supplies, capital equipment, or scientific travel. Deductions for administrative overhead or other indirect costs are not allowed from the grant. Payments are made quarterly in U.S. currency to the host institution, earmarked specifically for the principal investigators. Funding for the second year is contingent upon receipt of a satisfactory progress report after the first year.

The Immunotherapy Promise Investigators will be required to attend the annual CRI-CIMT-EATI-AACR International Immunotherapy Conference at least once during the funding period. Expenses related to attendance (registration, travel, hotel accommodations, and meals) will be reimbursed up to $5,000 per meeting, over and above the grant stipend.

Scientific Review of Applications
All grant proposals will be subject to rigorous peer review by a joint CRI/ICRF scientific review panel (JSRP), but the application and granting processes will be administered by the ICRF. Applications will be considered for funding on the basis of the overall merit of the proposal as determined by the JSRP, relevance of the proposal to the research objectives of the ICRF, CRI and this special program, and the availability of funds. Acting upon the recommendations of the JSRP, as well as the ICRF International Scientific Council, the Board of Trustees of the ICRF will then approve all awards jointly with CRI.

ONLY ONE (1) GRANT APPLICATION PER ISRAELI PRINCIPAL INVESTIGATOR WILL BE ACCEPTED FOR EACH SUBMISSION DEADLINE

(An Israeli investigator may submit a grant application for this special program in addition to one of the other, regular ICRF grant categories; but, if both applications are approved for funding, the applicant will only be allowed to receive one grant, and must decide which one to accept and which one to forfeit. If the applicant is a current ICRF grant recipient, then the current award may be forfeited for the new grant, provided that the new grant is for a different project.)
**Fiscal Requirements for Institution**

A separate account must be maintained for each award. This account must be available for audit at any time by representatives of the ICRF and/or CRI.

**Reporting**

An annual narrative and financial report from each institution involved, detailing the progress made and allocation of funds, will be required 11 months after the start of the funding period. ICRF will send forms directly to each institution. Reports will be shared and evaluated with CRI.

**Special Conditions**

Should the awardee(s) or the sponsoring institution(s) specified by our award vacate the project, the ICRF and CRI will automatically void the award and terminate funding. Failure of the institution(s) to notify the ICRF of such vacancy will allow the ICRF and CRI to recover funds *in toto*.

**Biohazards and Protection of Human Subjects/Animals**

Safeguarding the rights and welfare of human subjects involved in activities supported by the ICRF and CRI, as well as consideration of potential biohazards, is the responsibility of the institution(s) that received the award. Awards for projects involving human subjects and/or animals require prior review and approval by the appropriate institutional committee. Such written approvals must be submitted along with the grant application. The review date should be recent; certification is invalid if the review date precedes the submission date by more than one year. These approval letters must be written *in English*.

**Publications**

Publications resulting from research projects supported by the ICRF and CRI must contain the following acknowledgment:

"*This study was supported by an Immunotherapy Promise Grant, a partnership of the Israel Cancer Research Fund and the Cancer Research Institute.*"

Awardees should send electronic copies of publications carrying the above credit line to the ICRF International Executive Office in New York as soon as possible after publication.

**Patents**

Any decisions concerning intellectual property created or developed under The Immunotherapy Promise, including but not limited to ownership, responsibility for patent prosecution or other statutory protection, and if applicable, commercialization, will be reviewed in consultation between CRI and ICRF.

**Changes and Amendments**

Any changes or amendments to the original award must be approved in writing by the ICRF and CRI.

###